BiGEN participated in Series A fundraising of Noile-Immune Biotech (NIB), a Japanese private biotech company located in Tokyo.

Noile-Immune Biotech (NIB) is a private biotechnology company focused on the development of next generation CAR-T cells for the treatment of solid cancers. NIB’s proprietary novel cell therapy platform, PRIME (PRoliferation-Inducing and Migration-Enhancing) technology expressing a particular combination of IL-7 and CCL19, is able to enhance anti-tumor potential by enabling accumulation of CAR-T cells, dendritic cells, and polyclonal host T cells specific to endogenous tumor antigens into the tumor site. In 2018, Takeda Pharmaceutical Company had an option agreement with NIB to exclusively license NIB’s original pipelines, NIB-102 and NIB-103.

For more information, please visit https://www.noile-immune.com/english/